Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects

Тканевая инженерия и клеточные методы лечения переломов и костных дефектов
Jose Perez, Dimitrios Kouroupis, Deborah J. Li, Thomas M. Best, Lee D. Kaplan, Diego Correa
2018-07-31

biomaterialsbone tissue engineeringcell-based therapiesdelayed fracture healingmesenchymal stem cells
Bone fractures and segmental bone defects are a significant source of patient morbidity and place a staggering economic burden on the healthcare system. The annual cost of treating bone defects in the US has been estimated to be $5 billion, while enormous costs are spent on bone grafts for bone injuries, tumors, and other pathologies associated with defective fracture healing. Autologous bone grafts represent the gold standard for the treatment of bone defects. However, they are associated with variable clinical outcomes, postsurgical morbidity, especially at the donor site, and increased surgical costs. In an effort to circumvent these limitations, tissue engineering and cell-based therapies have been proposed as alternatives to induce and promote bone repair. This review focuses on the recent advances in bone tissue engineering (BTE), specifically looking at its role in treating delayed fracture healing (non-unions) and the resulting segmental bone defects. Herein we discuss: (1) the processes of endochondral and intramembranous bone formation; (2) the role of stem cells, looking specifically at mesenchymal (MSC), embryonic (ESC), and induced pluripotent (iPSC) stem cells as viable building blocks to engineer bone implants; (3) the biomaterials used to direct tissue growth, with a focus on ceramic, biodegradable polymers, and composite materials; (4) the growth factors and molecular signals used to induce differentiation of stem cells into the osteoblastic lineage, which ultimately leads to active bone formation; and (5) the mechanical stimulation protocols used to maintain the integrity of the bone repair and their role in successful cell engraftment. Finally, a couple clinical scenarios are presented (non-unions and avascular necrosis-AVN), to illustrate how novel cell-based therapy approaches can be used. A thorough understanding of tissue engineering and cell-based therapies may allow for better incorporation of these potential therapeutic approaches in bone defects allowing for proper bone repair and regeneration.
1
Autologous bone grafts remain the clinical gold standard but have variable outcomes, donor-site morbidity, and increased surgical costs.
2
Ceramics, biodegradable polymers, and composite biomaterials can direct tissue growth, while growth factors and molecular signals promote osteoblastic differentiation.
3
Mechanical stimulation protocols help maintain repair integrity and support successful cell engraftment; clinical applications include non-unions and avascular necrosis.
4
Mesenchymal, embryonic, and induced pluripotent stem cells are identified as potential building blocks for engineered bone implants.
5
Tissue engineering and cell-based therapies are presented as alternatives to promote repair of delayed unions and segmental bone defects.

Bone tissue engineering and cell-based therapies for delayed fracture healing and segmental bone defects

The therapeutic mechanisms, components, and clinical application of engineered bone repair, including stem cells, biomaterials, growth factors, and mechanical stimulation

Publication Details
Publication Date
2018-07-31
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Jose Perez
Dimitrios Kouroupis
Deborah J. Li
Thomas M. Best
Lee D. Kaplan
Diego Correa
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%